张晓进，博士，副教授，药物化学专业博士生导师，现任理学院化学系副主任。英国牛津大学（University of Oxford）化学系访问****。主持国家自然科学基金3项。以第一或通讯作者在药物化学领域国际知名刊物Journal of Medicinal Chemistry、European Journal of Medicinal Chemistry、Drug Discovery Today等发表SCI论文40余篇；已授权中国发明专利5项、欧洲专利1项、日本专利1项。作为主要负责人之一设计研发的抗肾性贫血新药目前正在中国开展I期临床试验。
曾获江苏省科学技术一等奖（2015）、国家科技进步奖二等奖（2016）、江苏省优青（2016）、中国药学会-施维雅青年药物化学奖（2016）、江苏省青蓝工程优秀青年骨干教师（2017）、江苏省“333高层次人才”（2018）、江苏省“六大人才高峰”高层次人才（2019）、南京药学会“青年科技之星”（2019）。
研究生招生方向：新药分子设计与合成
主要研究方向：围绕细胞“氧感知通路”及“氧化还原系统”开展靶向新药研发及化学生物学研究
联系方式：zxj@cpu.edu.cn 办公室：江宁校区化学楼C409
近年代表性论文:
1. Kaijun Su, Zhihong Li, Yancheng Yu, Xiaojin Zhang.*The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.Drug Discovery Today2020, 25 (7), 1262–1269.
2. Xiaojin Zhang, ^1,*Yonghua Lei,¹Tianhan Hu, Yue Wu, Zhihong Li, Zhensheng Jiang, Changyong Yang, Lianshan Zhang, Qidong You.* Discovery of clinical candidate (5-(3-(4-chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an orally bioavailable prolyl hydroxylase inhibitor for the treatment of anemia. Journal of Medicinal Chemistry2020, 63 (17), 10045–10060.
3. Zhihong Li, Shuai Zhen, Kaijun Su, Anthony Tumber, Quanwei Yu, Ying Dong, Michael McDonough, Christopher J. Schofield,* Xiaojin Zhang.* A small-molecule probe for monitoring binding to prolyl hydroxylase domain 2 by fluorescence polarisation. Chemical Communications2020, DOI: 10.1039/D0CC06353C
4. Qijie Gong, Jiabao Hu, Pengfei Wang, Xiang Li,* Xiaojin Zhang.* A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.European Journal of Medicinal Chemistry 2020, DOI: 10.1016/j.ejmech.2020.112962
5. Zhihong Li, Kaijun Su, Zhensheng Jiang, Yancheng Yu, Qidong You,* Xiaojin Zhang.* Photoactivatable prolyl hydroxylase 2 inhibitors for stabilizing the hypoxia-inducible factor with light. Journal of Medicinal Chemistry2019, 62(16), 7583?7588. (front cover)
6. Zhihong Li, Qidong You,* Xiaojin Zhang.* Small-molecule modulators of the hypoxia-inducible factor pathway: Development and therapeutic applications.Journal of Medicinal Chemistry2019, 62(12), 5725?5749.
7. Yancheng Yu, Quanwei Yu, Xiaojin Zhang.* Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma. Drug Discovery Today2019, 24 (12), 2332?2340.
8. Zhensheng Jiang, Qidong You,* Xiaojin Zhang.* Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective.European Journal of Medicinal Chemistry2019, 165, 172?197.
9. Xingsen Wu, Xiang Li, Zhihong Li, Yancheng Yu, Qidong You,* Xiaojin Zhang.* Discovery of nonquinone substrates for NAD(P)H: quinone oxidoreductase 1 (NQO1) as effective intracellular ROS generators for the treatment of drug-resistant non-small cell lung cancer. Journal of Medicinal Chemistry2018, 61(24), 11280?11297. (supplementary cover)
10. Yue Wu, Zhensheng Jiang, Zhihong Li, Jing Gu, Qidong You,* Xiaojin Zhang.* Click chemistry–based discovery of [3-hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as orally active hypoxia inducing factor prolyl hydroxylase inhibitors with favorable safety profiles for the treatment of anemia. Journal of Medicinal Chemistry2018, 61(12), 5332?5349.
11. Xian Zhang, ¹Xiang Li, ¹ Zhihong Li, Xingsen Wu, Yue Wu, Qidong You,* Xiaojin Zhang.* An NAD(P)H: quinone oxidoreductase 1 responsive and self-immolative prodrug of 5-fluorouracil for safe and effective cancer therapy.Organic Letters2018, 20(12), 3635?3638.
12. Jinlei Bian,¹Xiang Li,¹Nan Wang, Xingsen Wu, Qidong You,* Xiaojin Zhang.*Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile. European Journal of Medicinal Chemistry, 2017, 129, 27?40.
13. Jinlei Bian,¹Xiang Li,¹ Lili Xu，Nan Wang, Xue Qian, Qidong You,* Xiaojin Zhang.*Affinity-based smallfluorescent probefor NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation. European Journal of Medicinal Chemistry, 2017, 127, 828?839.
14. Xian Zhang, Xiang Li, Qidong You,* Xiaojin Zhang.*Prodrug strategy for cancer cell-specific targeting: a recent overview. European Journal of Medicinal Chemistry, 2017, 139, 542?563.